PARProceedings of Anticancer Research2208-35452208-3553Bio-Byword Scientific Publishing Pty. Ltd.10.26689/par.v7i6.5523ArticleAssessing the Effectiveness of Montelukast Sodium in Managing Pulmonary Infections in Lung Cancer Patientshttps://artdesignp.com/journal/PAR/7/6/10.26689/par.v7i6.5523XuRui,WangLi,HuangZhuan,ZhangYurong,HuangLingjuan2023762023-11-22Objective: To investigate the efficacy of montelukast sodium in the treatment of lung cancer patients with pulmonary infections. Methods: A total of 330 patients diagnosed with lung cancer and pulmonary infection, who were admitted to the First Affiliated Hospital of Xi’an Medical University from 2020 to 2022, were selected as research subjects. They were randomly divided into two groups: a control group receiving conventional treatment and an observation group receiving conventional treatment combined with montelukast sodium. Each group consisted of 165 cases. The time required for clinical symptom improvement, the resolution of lung infection signs, and the levels of serum inflammatory factors before and after treatment were compared between the two groups. Results: The observation group exhibited significantly faster improvement in clinical symptoms compared to the control group (P < 0.001). ELISA assays were conducted to detect the expression levels of IL-1β, IL-6, IL-8, and TNF-α in the serum of both groups at 1 week and 2 weeks into the treatment. The results indicated that, as the treatment progressed, the observation group displayed significantly lower levels of the four serum inflammatory factors compared to the control group (P < 0.001). Conclusion: Montelukast sodium demonstrates efficacy in the treatment of patients with lung cancer complicated by pulmonary infections. These findings suggest its potential for further verification and clinical application.

Liu D, Jiang D, Zhou X, et al., 2021, Comparison of Lung Cancer Mortality Between Rural and Urban Areas in the Mainland of China from 2004 to 2018. Shanghai Journal of Preventive Medicine, 33(10): 893–898.

Tang C, Lei H, Zhang J, et al., 2918, Montelukast Inhibits Hypoxia Inducible Factor-1? Translation in Prostate Cancer Cells. Cancer Biol Ther, 19(8): 715–721. https://doi.org/10.1080/15384047.2018.1451279

Bellamkonda K, Satapathy SR, Douglas D, et al., 2018, Montelukast, a CysLT1 Receptor Antagonist, Reduces Colon Cancer Stemness and Tumor Burden in a Mouse Xenograft Model of Human Colon Cancer. Cancer Lett, 437: 13–24.

Yang L, Ye B, Wei X, et al., 2016, Interpretation of the Latest Revised Version of the International TNM Staging Criteria for Lung Cancer (8th edition). Chinese Medical Journal, 51(9): 22–25.

Siegel RL, Miller KD, Fuchs HE, et al., 2022, Cancer Statistics, 2022. CA Cancer J Clin, 72(1): 7–33. https://doi.org/10.3322/caac.21708

Chen Y, Zhang J, Wei S, 2023, Montelukast Inhibits Lung Cancer Cell Migration by Suppressing Cysteinyl Leukotriene Receptor 1 Expression in vitro. Curr Pharm Biotechnol, 24(10): 1335–1342.https://doi.org/10.2174/1389201024666221207143513

Xia C, Dong X, Li H, et al., Cancer Statistics in China and United States, 2022: Profiles, Trends, and Determinants. Chin Med J (Engl), 135(5): 584–590. https://doi.org/10.1097/CM9.0000000000002108

Zhu H-Z, Zhou W-J, Wan Y-F, et al., 2020, Downregulation of Orosomucoid 2 Acts as a Prognostic Factor Associated with Cancer-Promoting Pathways in Liver Cancer. World J Gastroenterol, 26(8): 804–817. https://doi.org/10.3748/wjg.v26.i8.804

Chen W-W, Qi J-W, Hang Y, et al., 2020, Simvastatin is Beneficial to Lung Cancer Progression by Inducing METTL3-Induced m6A Modification on EZH2 mRNA. Eur Rev Med Pharmacol Sci, 24(8): 4263–4270. https://doi.org/10.26355/eurrev_202004_21006

Zhu W, Wang J-P, Meng Q-Z, et al., 2020, MiR-142-5P Reverses the Resistance to Gefitinib Through Targeting HOXD8 in Lung Cancer Cells. Eur Rev Med Pharmacol Sci, 24(8): 4306–4313. https://doi.org/10.26355/eurrev_202004_21011

Wang H, 2019, Effects of Budesonide and Formoterol Combined with Montelukast Sodium on Serum IL-6 and TNF-? Levels and Lung Function in Patients with Cough Variant Asthma. Journal of Guizhou Medical University, 44(2): 243–248.

Lillienberg L, Andersson E, Janson C, et al., 2013, Occupational Exposure and New-Onset Asthma in a Population-Based Study in Northern Europe (RHINE). Ann Occup Hyg, 57(4): 482–492.https://doi.org/10.1093/annhyg/mes083

Zhou X, Hong J, Cheng H, et al., 2016, Budesonide Suspension Nebulization Treatment in Chinese Pediatric Patients with Cough Variant Asthma: A Multi-Center Observational Study. Journal of Asthma Official Journal of the Association for the Care of Asthma, 53(5): 527–532.

Tsai M-J, Chang W-A, Tsai P-H, et al., 2017, Montelukast Induces Apoptosis-Inducing Factor-Mediated Cell Death of Lung Cancer Cells. Int J Mol Sci, 18(7): 1353. https://doi.org/10.3390/ijms18071353

Li D, Li Y, Guo Y, et al., 2016, Analysis of Laboratory Detection Indicators of Pulmonary Infection in Chronic Obstructive Pulmonary Disease. International Journal of Laboratory Medicine, 37(2): 166–168.

Li H, Meng J, Tang L, et al., 2020, Exploring the Differences in Blood Routine Indicators and Serum Inflammatory Factors in Patients with Lung Cancer and Lung Cancer Combined with Pulmonary Infection. Modern Chinese Doctors, 58(24): 113–115.

Xu X, Liu D, Shi M, 2020, Research Progress on the Relationship Between IL-1? and the Malignant Evolution of Tumors. Chinese Journal of Immunology, 2020(11): 1387–1391.

Zhao P, Li J, Tian Y, et al., 2018, Restoring Th17 /Treg Balance via Modulation of STAT3 and STAT5 Activation Contributes to the Amelioration of Chronic Obstructive Pulmonary Disease by Bufei Yishen Formula. J Ethnopharmacol, 217: 152–162. https://doi.org/10.1016/j.jep.2018.02.023

Wang X, Xiao Q, Chen K, et al., 2020, IL-8 and the Occurrence, Development, and Treatment of Tumors. Journal of Henan University (Medical Edition), 39(6): 436–439.

Huang M, Wang X, Lu Y, 2023, Expression of TNF-? and FOXA2 Proteins in Colorectal Cancer Tissues and Their Clinical Significance. Carcinogenesis Aberration Mutation, 35(4): 296–301.

Li S, An S, Guo F, et al., 2018, Study on the Correlation Between Serum TNF-?, IL-6 and Coagulation Function in Patients with Lung Cancer. Journal of Practical Cancer, 33(11): 1173–1176.

Pan J, Zhan C, Yuan T, et al., 2018, Effects and Molecular Mechanisms of Intrauterine Infection/Inflammation on Lung Development. Respir Res, 19(1): 93. https://doi.org/1-.1186/s12931-018-0787-y

Wang C, Chen C, Pang X, 2019, Changes and Clinical Significance of Serum CRP, TNF-?, and IL-2 Levels in Patients with Postoperative Lung Infection and Lung Cancer. Cancer Progress, 17(19): 2296–2301.

Shiroyama T, Suzuki H, Tamiya M, et al., 2018, Pretreatment Advanced Lung Cancer Inflammation Index (ALI) for Predicting Early Progression in Nivolumab-Treated Patients with Advanced Non-Small Cell Lung Cancer. Cancer Med, 7(1): 13–20. https://doi.org/10.1002/cam4.1234